Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.32

-1.1%

Dec 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1816)	10/4/2007 11:01:30 AM
From: Jibacoa	Read Replies (1) of 3722

CVTX Has been forming a base at the $9.10 level.<g> bigcharts.marketwatch.com It has applied to the FDA for a revision on the label for its Ranexa for the treatment of angina as it believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. (Ranexa is currently approved for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.) The problem CVTX has with Ranexa is that some insurance companies have been reluctant to cover the drug or have it as a non-preferred treatment. But if the FDA does approve the change in labeling, (the decision is expected next year)the sales of Ranexa should benefit as there are about 9M patients treated for angina mainly with generic drugs. With the FDA approval, it seems there is a chance for CVTX to have a 50% gain from present levels.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next